UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

Journal of the advanced practitioner in oncology, 2019-03, Vol.10 (2), p.167-174

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

Journal of Immunotherapy and Precision Oncology, 2022-08, Vol.5 (3), p.52-57

2022

Link zum Volltext

Verfügbarkeit prüfen

255 Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A277-A278

2020

Link zum Volltext

Verfügbarkeit prüfen

223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A242-A242

2020

Link zum Volltext

Verfügbarkeit prüfen

44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A45-A46

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

Cancer treatment and research communications, 2021, Vol.28, p.100393-100393, Article 100393

2021

Link zum Volltext

Verfügbarkeit prüfen

45 Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A47-A48

2020

Link zum Volltext

Verfügbarkeit prüfen

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors.(INSIGHTS FROM AN ONCOLOGY PHARMACIST)(poly (adenosine diphosphate-ribose) polymerase)

Oncology (Williston Park, N.Y.), 2019-02, Vol.33 (2), p.58

2019

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Journal of the advanced practitioner in oncology, 2019-07, Vol.10 (5), p.501-507

2019

Link zum Volltext

Verfügbarkeit prüfen

The impact of body mass index (BMI) on the safety and outcomes of small molecule inhibitors (SMI) in gastrointestinal cancer

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.144-144

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of basophil to lymphocyte ratio (BLR) with clinical outcomes in metastatic hormone sensitive prostate cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17049-e17049

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16570-e16570

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16546-e16546

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16569-e16569

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.544-544

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.340-340

2022

Link zum Volltext

Verfügbarkeit prüfen

Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.734-734

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.738-738

2020

Link zum Volltext

Verfügbarkeit prüfen

Honor, Status, and Law in Modern Latin America

1, 2005

Link zum Volltext

Verfügbarkeit prüfen

Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16068-e16068

2019

Link zum Volltext

Verfügbarkeit prüfen

Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.612-612

2019

Link zum Volltext

Verfügbarkeit prüfen

Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.613-613

2019

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.390-390

2019

Link zum Volltext

Verfügbarkeit prüfen

Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.472-472

2019

Link zum Volltext

Verfügbarkeit prüfen

Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.671-671

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 117

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Humans
(10)
Multidisciplinary Sciences
(10)
Science & Technology - Other Topics
(10)
Latin America
(9)
Social Status
(7)
Immunotherapy
(6)
Law
(6)
Clinical Outcomes
(5)
Animals
(4)
Biology
(4)
Cancer
(4)
Female
(4)
Genome-Wide Association Study
(4)
Genomes
(4)
Honor
(4)
Honour And Shame
(4)
Kidney Cancer
(4)
Male
(4)
Metastasis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

255 Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies

223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

45 Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI)

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors.(INSIGHTS FROM AN ONCOLOGY PHARMACIST)(poly (adenosine diphosphate-ribose) polymerase)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

The impact of body mass index (BMI) on the safety and outcomes of small molecule inhibitors (SMI) in gastrointestinal cancer

Association of basophil to lymphocyte ratio (BLR) with clinical outcomes in metastatic hormone sensitive prostate cancer

Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting

Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)

Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)

Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI)

Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma

Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C)

Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)

Honor, Status, and Law in Modern Latin America

Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo)

Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo)

Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO)

Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO)

Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts)

Aktive Filter

Suchergebnisse filtern